Live / Latest

‘CoroFlu’: Bharat Biotech’s one drop intranasal vaccine under development

Hyderabad, Apr 3: Hyderabad-based vaccine maker Bharat Biotech Friday said that a unique intranasal vaccine for Coronavirus ‘CoroFlu’ is under development. An international collaboration of virologists at the University of Wisconsin–Madison (US) and the vaccine companies FluGen along with Bharat Biotech has begun the development and testing of the vaccine. CoroFlu is a one drop COVID-19 nasal vaccine built on a flu vaccine “backbone” that has been shown to be safe and well-tolerated in humans, in Phase I and Phase II clinical trials, the Hyderabad-headquartered vaccine maker said. CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR. Based on an invention by UW­–Madison virologists and FluGen co-founders Yoshihiro Kawaoka and Gabriele Neumann, M2SR is a self-limiting version of the influenza virus that induces an immune response against the flu. Kawaoka’s lab will insert gene sequences from SARS-CoV-2, the novel Coronavirus that causes the disease COVID-19, into M2SR so that the new vaccine will also induce immunity against the Coronavirus. Sharing details about ‘CoroFlu’ collaboration Dr Raches Ella, head, Business Development, Bharat Biotech said, “Bharat Biotech...